GeoVax Labs Prioritizes Development of GEO-MVA and Gedeptin
GeoVax Labs announced earlier today a strategic prioritization of its development portfolio to concentrate resources on its lead programs, GEO-MVA and Gedeptin. As part of this decision, the company has elected to discontinue development activities related to its GEO-CM04S1 COVID-19 vaccine candidate. "This decision was not related to any safety concerns with the vaccine but reflects the continued evolution and contraction of the global COVID-19 vaccine market, and GeoVax's focus on programs with clearer regulatory pathways, stronger demand visibility, and more immediate commercialization potential," the company said in a statement. It added, "As GEO-MVA advances toward clinical validation and potential commercialization, and as Gedeptin gains relevance within emerging immuno-oncology treatment paradigms, we are aligning our resources to support focused execution against these high-potential opportunities." GEO-MVA is GeoVax's modified vaccinia ankara vaccine candidate targeting mpox and smallpox, which is advancing under an expedited regulatory pathway supported by European Medicines Agency scientific advice.
